Daiken Biomedical (大研生醫) reported record-breaking 2025 results, with annual revenue reaching NT$1.89 billion (+38.57% YoY). The primary driver was the explosive expansion in the Japanese market, which saw Q4 revenue surge 153.98% compared to Q3.

Key Performance Drivers:

• E-commerce Synergy: The "dual-engine" approach of the official Japanese website and Amazon Japan proved highly effective. The brand was recently awarded the "Best Biomedical Brand" by Amazon Japan.
• Supply Chain Optimization: Demand for the core "High-Concentration Fish Oil" exceeded expectations, leading to temporary stock shortages. The company has initiated capacity expansion, with normal supply levels expected to resume by February.

Chairman Jerry Chang emphasized that the 2026 focus will remain on deepening the Japanese footprint and leveraging this international success to sustain long-term growth.

Resource: 大研生醫2025年營收創歷史新高 日本市場成長爆發力驚人